371 related articles for article (PubMed ID: 31451332)
1. Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts.
Drost FH; Nieboer D; Morgan TM; Carroll PR; Roobol MJ;
Eur Urol; 2019 Nov; 76(5):693-702. PubMed ID: 31451332
[TBL] [Abstract][Full Text] [Related]
2. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
[TBL] [Abstract][Full Text] [Related]
3. Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance.
Tomer A; Nieboer D; Roobol MJ; Bjartell A; Steyerberg EW; Rizopoulos D;
BJU Int; 2021 Jan; 127(1):96-107. PubMed ID: 32531869
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.
Lin DW; Newcomb LF; Brown MD; Sjoberg DD; Dong Y; Brooks JD; Carroll PR; Cooperberg M; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y;
Eur Urol; 2017 Sep; 72(3):448-454. PubMed ID: 27889277
[TBL] [Abstract][Full Text] [Related]
5. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
6. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.
Gayet M; Mannaerts CK; Nieboer D; Beerlage HP; Wijkstra H; Mulders PFA; Roobol MJ
Eur Urol Focus; 2018 Mar; 4(2):228-234. PubMed ID: 28753781
[TBL] [Abstract][Full Text] [Related]
7. Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability.
Cooperberg MR; Zheng Y; Faino AV; Newcomb LF; Zhu K; Cowan JE; Brooks JD; Dash A; Gleave ME; Martin F; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Carroll PR; Lin DW
JAMA Oncol; 2020 Oct; 6(10):e203187. PubMed ID: 32852532
[TBL] [Abstract][Full Text] [Related]
8. Risk-Based Selection for Active Surveillance: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Initiative.
Bruinsma SM; Nieboer D; Roobol MJ; Bangma CH; Verbeek JFM; Gnanapragasam V; Van Hemelrijck M; Frydenberg M; Lee LS; Valdagni R; Logothetis C; Steyerberg EW;
J Urol; 2021 Jul; 206(1):62-68. PubMed ID: 33617330
[TBL] [Abstract][Full Text] [Related]
9. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
Cooperberg MR; Brooks JD; Faino AV; Newcomb LF; Kearns JT; Carroll PR; Dash A; Etzioni R; Fabrizio MD; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW; Zheng Y
Eur Urol; 2018 Aug; 74(2):211-217. PubMed ID: 29433975
[TBL] [Abstract][Full Text] [Related]
10. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study.
Kearns JT; Faino AV; Newcomb LF; Brooks JD; Carroll PR; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y; Lin DW
Eur Urol; 2018 May; 73(5):706-712. PubMed ID: 29433973
[TBL] [Abstract][Full Text] [Related]
11. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
Roobol MJ; Verbeek JFM; van der Kwast T; Kümmerlin IP; Kweldam CF; van Leenders GJLH
Eur Urol; 2017 Jul; 72(1):45-51. PubMed ID: 28162815
[TBL] [Abstract][Full Text] [Related]
12. Phi-based risk calculators performed better in the prediction of prostate cancer in the Chinese population.
Wu YS; Fu XJ; Na R; Ye DW; Qi J; Lin XL; Liu F; Gong J; Zhang N; Jiang GL; Jiang HW; Ding Q; Xu J; Sun YH
Asian J Androl; 2019; 21(6):592-597. PubMed ID: 30924451
[TBL] [Abstract][Full Text] [Related]
13. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
[TBL] [Abstract][Full Text] [Related]
14. Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS).
Newcomb LF; Zheng Y; Faino AV; Bianchi-Frias D; Cooperberg MR; Brown MD; Brooks JD; Dash A; Fabrizio MD; Gleave ME; Liss M; Morgan TM; Thompson IM; Wagner AA; Carroll PR; Nelson PS; Lin DW
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):438-445. PubMed ID: 30664734
[TBL] [Abstract][Full Text] [Related]
15. Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer.
Lonergan PE; Washington SL; Cowan JE; Zhao S; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
J Urol; 2020 Dec; 204(6):1216-1221. PubMed ID: 32519915
[TBL] [Abstract][Full Text] [Related]
16. Understanding the Use of Prostate Biopsy Among Men with Limited Life Expectancy in a Statewide Quality Improvement Collaborative.
Abdollah F; Ye Z; Miller DC; Linsell SM; Montie JE; Peabody JO; Ghani KR;
Eur Urol; 2016 Nov; 70(5):854-861. PubMed ID: 27113032
[TBL] [Abstract][Full Text] [Related]
17. Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.
Inoue LYT; Lin DW; Newcomb LF; Leonardson AS; Ankerst D; Gulati R; Carter HB; Trock BJ; Carroll PR; Cooperberg MR; Cowan JE; Klotz LH; Mamedov A; Penson DF; Etzioni R
Ann Intern Med; 2018 Jan; 168(1):1-9. PubMed ID: 29181514
[TBL] [Abstract][Full Text] [Related]
18. Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer.
Masic S; Cowan JE; Washington SL; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
Eur Urol Oncol; 2018 Oct; 1(5):386-394. PubMed ID: 31158077
[TBL] [Abstract][Full Text] [Related]
19. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore.
Verbeek JFM; Bangma CH; Kweldam CF; van der Kwast TH; Kümmerlin IP; van Leenders GJLH; Roobol MJ
Urol Oncol; 2019 Feb; 37(2):138-144. PubMed ID: 30528698
[TBL] [Abstract][Full Text] [Related]
20. External Validation and Comparison of Prostate Cancer Risk Calculators Incorporating Multiparametric Magnetic Resonance Imaging for Prediction of Clinically Significant Prostate Cancer.
Saba K; Wettstein MS; Lieger L; Hötker AM; Donati OF; Moch H; Ankerst DP; Poyet C; Sulser T; Eberli D; Mortezavi A
J Urol; 2020 Apr; 203(4):719-726. PubMed ID: 31651228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
